This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, J. L. Articles by Mantzoros, C. S. Search for Related Content PubMed PubMed Citation Articles by Chan, J. L. Articles by Mantzoros, C. S. Related Collections Neuroendocrinology and Pituitary Obesity

Recombinant Methionyl Human Leptin Administration to Achieve High Physiologic or Pharmacologic Leptin Levels Does Not Alter Circulating Inflammatory Marker Levels in Humans with Leptin Sufficiency or Excess

Division of Endocrinology, Diabetes, and Metabolism (J.L.C., J.B., V.S., C.A., C.S.M.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; and Amgen, Inc. (A.M.D.), Thousand Oaks, California 91320

Address all correspondence and requests for reprints to: Dr. Christos S. Mantzoros, Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, ST 816, Boston, Massachusetts 02215. E-mail: cmantzor{at}bidmc.harvard.edu.

A role for high leptin levels in the proinflammatory state associated with obesity has been proposed on the basis of observational studies, but a recent interventional study employing administration of long-acting pegylated leptin resulting in very high pharmacologic levels in obese subjects did not support this idea. These interventional studies have not yet been independently confirmed, however, and varying levels and duration of hyperleptinemia as well as the presence of comorbidities such as diabetes have not yet been investigated as potential effect modifiers. We performed three interventional studies involving administration of recombinant methionyl human leptin (r-metHuLeptin) to lean, otherwise healthy obese, and obese diabetic subjects to investigate whether increasing circulating leptin levels over a wide spectrum of values (from low physiologic to high pharmacologic) would alter serum levels of inflammatory markers and other cytokines important in the T helper cell response. Increasing leptin levels from low physiologic to high physiologic in lean men and from higher physiologic to low pharmacologic in obese men over 3 d did not alter serum interferon-, IL-10, TNF-, monocyte chemoattractant protein-1, or soluble intercellular adhesion molecule-1. In obese subjects with type 2 diabetes mellitus, the administration of r-metHuLeptin for 4 or 16 wk, resulting in high pharmacologic leptin levels, did not activate the TNF- system or increase cytokines or inflammatory markers, including IL-10, IL-6, C-reactive protein, monocyte chemoattractant protein-1, and soluble intercellular adhesion molecule-1. These findings do not support an etiopathogenic role for leptin in proinflammatory states associated with leptin excess such as obesity and have direct relevance for the potential future therapeutic use of r-metHuLeptin in humans.

This article has been cited by other articles:

				E. Th. Petridou, T. N. Sergentanis, N. Dessypris, I. T. Vlachantoni, S. Tseleni-Balafouta, A. Pourtsidis, M. Moschovi, S. Polychronopoulou, F. Athanasiadou-Piperopoulou, M. Kalmanti, et al. Serum Adiponectin As a Predictor of Childhood Non-Hodgkin's Lymphoma: A Nationwide Case-Control Study J. Clin. Oncol., October 20, 2009; 27(30): 5049 - 5055. [Abstract] [Full Text] [PDF]

				S. Bluher and C. S Mantzoros Leptin in humans: lessons from translational research Am. J. Clinical Nutrition, March 1, 2009; 89(3): 991S - 997S. [Abstract] [Full Text] [PDF]

				L. Pacifico, L. Di Renzo, C. Anania, J. F Osborn, F. Ippoliti, E. Schiavo, and C. Chiesa Increased T-helper interferon-{gamma}-secreting cells in obese children. Eur. J. Endocrinol., May 1, 2006; 154(5): 691 - 697. [Abstract] [Full Text] [PDF]

				E. A. Oral, E. D. Javor, L. Ding, G. Uzel, E. K. Cochran, J. R. Young, A. M. DePaoli, S. M. Holland, and P. Gorden Leptin Replacement Therapy Modulates Circulating Lymphocyte Subsets and Cytokine Responsiveness in Severe Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 621 - 628. [Abstract] [Full Text] [PDF]

				B. Canavan, R. O. Salem, S. Schurgin, P. Koutkia, I. Lipinska, M. Laposata, and S. Grinspoon Effects of Physiological Leptin Administration on Markers of Inflammation, Platelet Activation, and Platelet Aggregation during Caloric Deprivation J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5779 - 5785. [Abstract] [Full Text] [PDF]

				J. Gomez-Ambrosi, J. Salvador, C. Silva, F. Rotellar, M. J. Gil, J. A. Cienfuegos, and G. Fruhbeck Leptin Therapy Does Not Affect Inflammatory Markers J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3803 - 3803. [Full Text] [PDF]

				J. L. Chan and C. S. Mantzoros Authors' Response: Leptin Therapy Does Not Affect Inflammatory Markers J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3803 - 3803. [Full Text] [PDF]